You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯環藥業(600513.SH)獲得藥物臨牀試驗批准通知書
格隆匯 11-27 16:17

格隆匯 11 月 27日丨聯環藥業(600513.SH)公佈,公司於近日收到國家藥監局核准簽發的關於 LH-1801 片(規格:10mg、 100mg)的《藥物臨牀試驗批准通知書》,並將於近期開展臨牀試驗。

LH-1801是一種新型SGLT2抑制劑,具有良好的體內降血糖作用,適應症為1 型及2型糖尿病。LH-1801是由中國科學院上海藥物研究所與江蘇聯環藥業股份有 限公司合作開發的I類具有我國自主知識產權的抗糖尿病候選新藥。經查詢,目 前有7個SGLT2抑制劑上市:阿斯利康的達格列淨、強生的坎格列淨、勃林格殷格翰的恩格列淨和默沙東的埃格列淨,另有安斯泰來製藥的伊格列淨、中外製藥的 託格列淨和大正製藥的魯格列淨僅在日本上市。經查詢PDB數據庫,2019年達格 列淨和恩格列淨的全球市場銷售額約40.72億美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account